Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 231

1.

Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.

Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group.

Menopause. 2013 Jun;20(6):623-30. doi: 10.1097/gme.0b013e318279ba64.

PMID:
23361170
2.
3.

Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.

Bachmann GA, Komi JO; Ospemifene Study Group.

Menopause. 2010 May-Jun;17(3):480-6. doi: 10.1097/gme.0b013e3181c1ac01.

PMID:
20032798
4.

The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis.

Cui Y, Zong H, Yan H, Li N, Zhang Y.

J Sex Med. 2014 Feb;11(2):487-97. doi: 10.1111/jsm.12377. Epub 2013 Nov 20. Review.

PMID:
24251418
5.

Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women.

Simon J, Portman D, Mabey RG Jr; Ospemifene Study Group.

Maturitas. 2014 Mar;77(3):274-81. doi: 10.1016/j.maturitas.2013.12.005. Epub 2013 Dec 17.

6.

One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.

Simon JA, Lin VH, Radovich C, Bachmann GA; Ospemifene Study Group.

Menopause. 2013 Apr;20(4):418-27. doi: 10.1097/gme.0b013e31826d36ba.

PMID:
23096251
7.

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.

Wurz GT, Kao CJ, DeGregorio MW.

Clin Interv Aging. 2014 Nov 13;9:1939-50. doi: 10.2147/CIA.S73753. eCollection 2014. Review.

8.

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.

Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA.

Climacteric. 2015 Apr;18(2):226-32. doi: 10.3109/13697137.2014.954996. Epub 2014 Sep 25.

9.

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.

Bruyniks N, Nappi RE, Castelo-Branco C, de Villiers TJ, Simon J.

Climacteric. 2016;19(1):60-5. doi: 10.3109/13697137.2015.1113517. Epub 2015 Nov 19.

10.

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy.

Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA.

Climacteric. 2015 Apr;18(2):233-40. doi: 10.3109/13697137.2014.975199. Epub 2014 Dec 16.

11.

Assessment of ospemifene or lubricants on clinical signs of VVA.

Constantine G, Graham S, Koltun WD, Kingsberg SA.

J Sex Med. 2014 Apr;11(4):1033-1041. doi: 10.1111/jsm.12428. Epub 2014 Jan 21.

PMID:
24443923
12.

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program.

Constantine GD, Goldstein SR, Archer DF.

Menopause. 2015 Jan;22(1):36-43. doi: 10.1097/GME.0000000000000275.

13.

Ospemifene in the treatment of vulvovaginal atrophy.

Barnes KN, Pearce EF, Yancey AM, Forinash AB.

Ann Pharmacother. 2014 Jun;48(6):752-7. doi: 10.1177/1060028014526036. Epub 2014 Mar 10. Review. Erratum in: Ann Pharmacother. 2014 Nov;48(11):1538.

PMID:
24615631
14.

Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.

McLendon AN, Clinard VB, Woodis CB.

Pharmacotherapy. 2014 Oct;34(10):1050-60. doi: 10.1002/phar.1465. Epub 2014 Jul 23. Review.

PMID:
25052122
15.

Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.

DeGregorio MW, Zerbe RL, Wurz GT.

Steroids. 2014 Nov;90:82-93. doi: 10.1016/j.steroids.2014.07.012. Epub 2014 Aug 1. Review.

PMID:
25087944
16.

Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.

Pinkerton JV, Kagan R.

Expert Opin Pharmacother. 2015;16(17):2703-14. doi: 10.1517/14656566.2015.1109627. Epub 2015 Dec 3. Review.

PMID:
26634778
17.

A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.

Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH.

Menopause. 2010 Mar;17(2):281-9. doi: 10.1097/GME.0b013e3181b7c65f.

PMID:
19779382
18.

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.

Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O; Ospemifene Study Group.

Climacteric. 2014 Apr;17(2):173-82. doi: 10.3109/13697137.2013.834493. Epub 2013 Nov 23.

19.

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.

Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É; VVA Prasterone Research Group.

Menopause. 2016 Mar;23(3):243-56. doi: 10.1097/GME.0000000000000571.

PMID:
26731686
20.

Profile of ospemifene in the breast.

Berga SL.

Reprod Sci. 2013 Oct;20(10):1130-6. doi: 10.1177/1933719113497290. Epub 2013 Aug 13. Review.

PMID:
23945733

Supplemental Content

Support Center